Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants.

[1]  D. Taruscio,et al.  Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation? , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  B. Quon,et al.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review , 2020, Journal of clinical medicine.

[3]  P. Negulescu,et al.  G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect , 2020, Clinical and translational science.

[4]  G. Lam,et al.  The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis , 2020, Annals of the American Thoracic Society.

[5]  D. Caimmi,et al.  Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.

[6]  A. Munck,et al.  Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  T. Noah,et al.  Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  S. Leroy,et al.  Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  C. Dryden,et al.  The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review , 2016, Archives of Disease in Childhood.

[10]  P. Hiatt,et al.  Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[12]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  J. Lehmann-Che,et al.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype , 2005, Human Genetics.

[14]  Y. Eto,et al.  A Japanese patient homozygous for the H1085R mutation in the CFTR gene presents with a severe form of cystic fibrosis , 1999, Clinical genetics.

[15]  Joseph F. Cotten,et al.  Effect of Cystic Fibrosis-associated Mutations in the Fourth Intracellular Loop of Cystic Fibrosis Transmembrane Conductance Regulator* , 1996, The Journal of Biological Chemistry.